Welcome, Introduction, and Baseline Assessment
Advances in ovarian cancer: evolving landscape for PARP inhibitors
Biomarkers in ovarian cancer; BRCA and beyond?
Clinical application of PARP inhibitors
Summary, Final Thoughts, Posteducation Assessment, and Audience
Question and Answer Session
Date / Time
Nicoletta Colombo, MD
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Philipp Harter, MD, PhD
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
The goal of this activity is to educate global gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.
This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
- Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
- Plan PARP inhibitor–based therapeutic strategies for patients with ovarian cancer based on available data, long-term clinical experience, expert recommendations, and patient preferences
- Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
- Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
- Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.